Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

What’s the Role of Epstein-Barr Virus Reactivation in Lupus Development?

Larry Beresford   |  Issue: November 2020  |  November 12, 2020

Other Factors

But the complete, complex relationship between EBV and SLE risk may also involve other factors, the researchers conclude. Future research in this area will include preventive trials, as well as pursuing additional natural history studies. Dr. James poses the question of whether early detection of disease could help identify appropriate target populations for research and intervention.

She is one of the researchers, along with principal investigators Nancy Olsen, MD, and David Karp, MD, PhD, in the promising, NIH-funded Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE). This double-blind, multi-center trial will examine patients with incomplete lupus receiving hydroxychloroquine, compared with placebo, to see if it could prevent them from acquiring additional clinical and immunological factors that define lupus.2

Dr. James

Dr. James

Researchers are also looking for associations of other infections with lupus—and other patient groups that aren’t related to a lupus patient. Another recent study conducted at Cincinnati Children’s Hospital Medical Center (CCHMC) and published last year in the journal Nature Genetics found associations between EBV-related transcription factors and six other medical conditions along with SLE.3 That study found EBV is associated with an increased risk of developing SLE, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, inflammatory bowel disease, celiac disease and type 1 diabetes—which together affect nearly 8 million people in the U.S. The study also found that a protein produced by EBV binds to multiple locations along the human genome associated with these seven conditions.

One of the leaders of that study, John B. Harley, MD, PhD, professor and director of the Center for Autoimmune Genomics and Etiology at CCHMC, says lupus is the signal disease in this research—“the one we start with.” Recent studies are convincing researchers that EBV is an important etiologic agent in the progression of SLE, and Dr. James’ research “is another step in the direction of trying to figure it out, consistent with the possibility EBV causes lupus,” Dr. Harley tells The Rheumatologist.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Our challenge now is to discover the mechanism for how and why that might happen,” Dr. Harley says. “What changes in our relationship with this relatively innocuous virus to cause that?”


Larry Beresford is a medical journalist in Oakland, Calif.

References

  1. Jog NR, Young KA, Munroe ME, et al. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Ann Rheum Dis. 2019 Sep;78(9):1235–1241.
  2. Olsen NJ, James JA, Arriens C, et al. Study of anti-malarials in incomplete lupus erythematosus (SMILE): Study protocol for a randomized controlled trial. Trials. 2018 Dec 20;19(1):694.
  3. Harley JB, Chen X, Pujato M, et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nature Genet. 2018 May;50(5):699–707.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Epstein-Barr virus (EBV)

Related Articles

    Rheumatology Case Report: Concomitant Lupus with Features of Scleroderma, Castleman Disease

    July 11, 2016

    We report a case of a 27-year-old woman who was initially diagnosed with systemic lupus erythematosus (SLE), had features of scleroderma and was subsequently found to have lymph node biopsy consistent with multicentric Castleman disease (MCD). She also had serologic evidence of acute Epstein-Barr virus (EBV) infection (vs. reactivation of EBV). The occurrence of MCD…

    Can Lupus Be Prevented? Research Reveals Clues to Who’s Most Likely to Transition to Classified Disease

    February 25, 2020

    How does a patient transition from health to active SLE? This question is the crux of the research conducted by Judith A. James, MD, PhD, and colleagues…

    Study Implicates Epstein-Barr Virus in 7 Autoimmune Diseases

    October 18, 2019

    The identification of specific transcription factors linked to the Epstein-Barr virus (EBV) provides new information on the molecular mechanisms underlying the link between EBV and autoimmune disease. A recently published study, “Transcrip­tion Factors Operate Across Disease Loci, with EBNA2 Implicated in Auto­immunity,” co-led by John B. Harley, MD, PhD; Leah C. Kottyan, PhD; and Matthew…

    Lupus often presents with a butterfly rash.

    Top 12: Research in Systemic Lupus Erythematosus at a Glance

    November 18, 2021

    Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences